Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

Publication date: Available online 23 October 2020Source: The Lancet NeurologyAuthor(s): Bruce A C Cree, Gary Cutter, Jerry S Wolinsky, Mark S Freedman, Giancarlo Comi, Gavin Giovannoni, Hans-Peter Hartung, Douglas Arnold, Jens Kuhle, Valerie Block, Frederick E Munschauer, Frédéric Sedel, Fred D Lublin, Stephen Reingold, Pierre Duquette, Tobias Derfuss, Franz Fazekas, Maria Pia Sormani, Robert P. Lisak, Jennifer Graves
Source: The Lancet Neurology - Category: Neurology Source Type: research